Evidence map›Paper›PMID 30333174›Full record

ArticleJournal of virology2019

Naturally Occurring Single Mutations in Ebola Virus Observably Impact Infectivity.

Gary Wong, Shihua He, Anders Leung, Wenguang Cao, Yuhai Bi, Zirui Zhang, Wenjun Zhu, Liang Wang, Yuhui Zhao, Keding Cheng and 5 more

Open access · hybridAbstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of virology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
3.2field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 44 citations in OpenAlex.

  1. Glycosylation of GETV E2 promotes pathogenesis in animal models.Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 5 institutions in 2 countries.

Gary Wong *Special Pathogens Program, Public Health Agency of Canada, Winnipeg, Manitoba, Canada.
Shihua He *Special Pathogens Program, Public Health Agency of Canada, Winnipeg, Manitoba, Canada.
Anders Leung *Special Pathogens Program, Public Health Agency of Canada, Winnipeg, Manitoba, Canada.
Wenguang Cao *Special Pathogens Program, Public Health Agency of Canada, Winnipeg, Manitoba, Canada.
Yuhai Bi *Shenzhen Key Laboratory of Pathogen and Immunity, Guangdong Key Laboratory for Diagnosis and Treatment of Emerging Infectious Diseases, Second Hospital Affiliated to Southern University of Science and Technology, Shenzhen Third People's Hospital, Shenzhen, China.
Zirui ZhangSpecial Pathogens Program, Public Health Agency of Canada, Winnipeg, Manitoba, Canada.
Wenjun ZhuSpecial Pathogens Program, Public Health Agency of Canada, Winnipeg, Manitoba, Canada.
Liang WangCAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Center for Influenza Research and Early Warning (CASCIRE), Chinese Academy of Sciences, Beijing, China.
Yuhui ZhaoCAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Center for Influenza Research and Early Warning (CASCIRE), Chinese Academy of Sciences, Beijing, China.
Keding ChengMonoclonal Antibody Unit, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba, Canada.
Di LiuCAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Center for Influenza Research and Early Warning (CASCIRE), Chinese Academy of Sciences, Beijing, China.
Wenjun LiuCAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Center for Influenza Research and Early Warning (CASCIRE), Chinese Academy of Sciences, Beijing, China.
Darwyn KobasaSpecial Pathogens Program, Public Health Agency of Canada, Winnipeg, Manitoba, Canada.
George F GaoShenzhen Key Laboratory of Pathogen and Immunity, Guangdong Key Laboratory for Diagnosis and Treatment of Emerging Infectious Diseases, Second Hospital Affiliated to Southern University of Science and Technology, Shenzhen Third People's Hospital, Shenzhen, China gaof@im.ac.cn xiangguo.qiu@canada.ca.
Xiangguo QiuSpecial Pathogens Program, Public Health Agency of Canada, Winnipeg, Manitoba, Canada gaof@im.ac.cn xiangguo.qiu@canada.ca.
Public Health Agency of Canada · CAUniversity of Manitoba · CAInstitute of Microbiology · CNChinese Academy of Sciences · CNShenzhen Third People’s Hospital · CN

Funding

Mechanistic Virology CoreU19AI109762 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI LAI, JONATHAN R. · 2014 to 2018
$29.6M
NIAID NIH HHS U19 AI109762
6 · The paper itself

Abstract

Sequencing of Ebola virus (EBOV) genomes during the 2014-2016 epidemic identified several naturally occurring, dominant mutations potentially impacting virulence or tropism. In this study, we characterized EBOV variants carrying one of the following substitutions: A82V in the glycoprotein (GP), R111C in the nucleoprotein (NP), or D759G in the RNA-dependent RNA polymerase (L). Compared with the wild-type (WT) EBOV C07 isolate, NP and L mutants conferred a replication advantage in monkey Vero E6, human A549, and insectivorous bat Tb1.Lu cells, while L mutants displayed a disadvantage in human Huh7 cells. The replication of the GP mutant was significantly delayed in Tb1.Lu cells and similar to that of the WT in other cells. The L mutant was less virulent, as evidenced by increased survival for mice and a significantly delayed time to death for ferrets, but increased lengths of the period of EBOV shedding may have contributed to the prolonged epidemic. Our results show that single substitutions can have observable impacts on EBOV pathogenicity and provide a framework for the study of other mutations.

Indexed as

Amino Acid SubstitutionA549 CellsAnimalsCell LineChiropteraChlorocebus aethiopsEbolavirusHumansVero CellsViral ProteinsVirulenceVirus ReplicationVirus SheddingViral ProteinsEbola virusferretsmicemutationspathogenicity

Identifiers

PMID30333174
PMCPMC6288345
OpenAlexW2896624720

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.